Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
381.8 SEK | +2.47% | +1.27% | +32.85% |
04-25 | Mycronic AB has Received Replacement Order for A Prexision 80 Evo from an Existing Customer in Asia | CI |
04-18 | Transcript : Mycronic AB, Q1 2024 Earnings Call, Apr 18, 2024 |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With a 2024 P/E ratio at 23.98 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Semiconductor Equipment & Testing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+32.85% | 3.4B | B- | ||
+25.98% | 360B | B | ||
+18.14% | 121B | B | ||
+35.54% | 101B | B+ | ||
+10.67% | 19.99B | C+ | ||
+5.56% | 18.87B | B+ | ||
+35.96% | 9.77B | B+ | ||
+24.11% | 9.34B | B | ||
-7.97% | 7.54B | C+ | ||
-23.57% | 6.08B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MYCR Stock
- Ratings Mycronic AB